Figure 1.
Size distribution (bars) and Z-potential (points) of DDA:TDB liposomal formulations with OVA±pIC/CpG.
Table 1.
Liposome specifications of the DDA:TDB formulations containing OVA and TLR agonists.
Figure 2.
Cellular and humoral responses following different liposome + OVA formulations.
The DDA:TDB+OVA formulations indicated along the X-axis were given to C57/BL6 mice as three homologous injections, two weeks apart. Splenocytes were isolated at the final timepoint (14 weeks) and responses to a CD8 OVA epitope (A) and two CD4 epitopes (B, C) were assessed by ex vivo IFNγ ELISpot. D) Total IgG antibody responses to whole OVA protein at the final time-point, as measured by an end-point titre ELISA. *p<0.05, ** p<0.01.
Figure 3.
Cellular and humoral responses to DDA:TDB liposomal formulations with OVA±TLR3 and TLR9 agonists.
Following three homologous injections of each DDA:TDB liposomal formulation, T cell and antibody responses were assessed at the terminal time-point (14 weeks). Mouse splenocytes were isolated and T cell responses to an OVA CD8 epitope (A) and two CD4 epitopes (B and C) measured by IFNγ ELISpot. D) Total IgG titre in the serum at the terminal timepoint, assessed by end-point ELISA. *p<0.05, **p<0.01.
Figure 4.
Cellular and humoral responses to liposome-adjuvanted viral vectored vaccines.
T cell and antibody responses were assessed in Balb/c mice at peak time-points for Adenovirus (Ad) and Modified Vaccinia Ankara (MVA) viral vectored vaccines expressing TIPeGFP, i.e. two weeks after a single injection of Ad and one week after two injections of MVA, combined with cationic DDA:TDB or neutral DSPC/TDB liposomes. Spleen T cell responses to two CD8 (A, B) and one CD4 epitope (C), contained within the insert of the viral constructs, were measured using IFNγ ELISpot. D) Total IgG titre in the serum of mice immunised with the Ad+liposome formulations at the peak time-point. **p<0.01.